Symbol="INAB"
AssetType="Common Stock"
Name="In8bioÂ Inc"
Description="IN8bio, Inc., a clinical-stage biotechnology company, is focused on developing new therapies for the treatment of cancers, including solid tumors using genetically modified, autologous, allogeneic gamma-delta T cells. The company is headquartered in New York, New York."
CIK="1740279"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="34212800"
EBITDA="-29214000"
PERatio="None"
PEGRatio="None"
BookValue="0.712"
DividendPerShare="0"
DividendYield="0"
EPS="-1.15"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.627"
ReturnOnEquityTTM="-1.259"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-1.15"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="13"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="1.956"
EVToRevenue="-"
EVToEBITDA="-1.368"
Beta="-0.226"
num_52WeekHigh="3.95"
num_52WeekLow="1.02"
num_50DayMovingAverage="1.591"
num_200DayMovingAverage="1.853"
SharesOutstanding="29750300"
DividendDate="None"
ExDividendDate="None"
symbol="INAB"
open="1.18"
high="1.18"
low="1.13"
price="1.13"
volume="69480.00"
latest_trading_day="2023-08-21"
previous_close="1.15"
change="-0.02"
change_percent="-1.7391%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="36"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="64"
Volume_recent_avg="2437115"
Change_recent_avg="-0.02"
Delta_recent_avg="0.21"
Variance_recent_avg="0.11"
Change_ratio_recent_avg="-1.43"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="64"
Aroon_momentum_negative="36"
image_negative_thumbnail_id_1="1159"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0193.jpeg"
image_negative_thumbnail_id_2="172"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0004.jpeg"
image_neutral_thumbnail_id_1="540"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0059.jpeg"
image_neutral_thumbnail_id_2="584"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0015.jpeg"
image_positive_thumbnail_id_1="1006"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0168.jpeg"
image_positive_thumbnail_id_2="1009"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0171.jpeg"
image_professor_thumbnail_id_1="1173"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0007.jpeg"
image_professor_thumbnail_id_2="1167"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0001.jpeg"
